case_images: PMC10324972_01
case_images: Therapy schedule of liposomal honokiol.
case_images: fneur-14-1172860-g0001.jpg
case_images: PMC10324972_01_fneur-14-1172860-g0001.jpg
case_images: F1
case_images: The therapy schedule is shown in Figure 1.
case_images: MRI images of the patient on 3rd March (A), 21st May (B), 4th August (C), and 15th November (D) 2021.
case_images: fneur-14-1172860-g0002.jpg
case_images: PMC10324972_01_fneur-14-1172860-g0002.jpg
case_images: F2
case_images: A new brain MRI after more than 2 months of therapy, on 21 May 2021, demonstrated no significant change in the lesion size in the left frontal lobe (Figure 2). On 4 August 2021, a follow-up craniocerebral MRI showed a mixed signal shadow and a pronounced surrounding edema in the left frontal lobe, while a T1-CE image showed a ring enhancement (Figure 2C). On 15 November, the patient was given bevacizumab combined with etoposide and carboplatin because of another tumor progression (Figure 2D).
case_images: Brain biopsy of the patient (A). The H&E staining of the same site (B).
case_images: fneur-14-1172860-g0003.jpg
case_images: PMC10324972_01_fneur-14-1172860-g0003.jpg
case_images: F3
case_images: Lesions were found in the frontal lobe, temporal lobe, and bilateral callosum (Figure 3A). On H&E staining, all lesions demonstrated the classic appearance of GBM, including nuclear atypia, palisading necrosis, and microvascular proliferation (Figure 3B).
case_images: Immunohistochemical stains of the patient's brain.
case_images: fneur-14-1172860-g0004.jpg
case_images: PMC10324972_01_fneur-14-1172860-g0004.jpg
case_images: F4
case_images: Moreover, a high Ki-67 expression (30%) was found in the tumor region (Figure 4).